Half-year report · Q2
4978.TEDINET S100UOVO
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 43
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥2.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥149m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥242m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥103m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥40m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥70m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥103m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥62m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥104m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥31m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥61m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥104m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥61m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥9.4bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥8.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥679m | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥741m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.0bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥131m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥11m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥58m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥412m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥404m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥46m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥681m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥544m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-1.14 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.37 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.71 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 92.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment ordinary income | 2024-04-01 → 2024-09-30 | −¥378m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥176m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥176m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥8m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥267m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| —segment total | segment ordinary income | 2024-04-01 → 2024-09-30 | ¥275m |
| Reconciling Itemsreconciling | segment ordinary income | 2023-04-01 → 2023-09-30 | −¥214m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥122m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥122m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥110m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥174m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | segment ordinary income | 2023-04-01 → 2023-09-30 | ¥284m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 483
| Item | Context | Value | Unit |
|---|---|---|---|
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 174249000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 110131000 | JPY |
| Ordinary income | Prior1YTDDuration_ReportableSegmentsMember | 284381000 | JPY |
| Ordinary income | Prior1YTDDuration_ReconcilingItemsMember | -214105000 | JPY |
| Ordinary income | Prior1YTDDuration | 70276000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 1144398000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 176014000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 1320413000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1320413000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 1144398000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 176014000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 1320413000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 1320413000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 267060000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 7507000 | JPY |
| Ordinary income | CurrentYTDDuration_ReportableSegmentsMember | 274567000 | JPY |
| Ordinary income | CurrentYTDDuration_ReconcilingItemsMember | -377824000 | JPY |
| Ordinary income | CurrentYTDDuration | -103257000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第23期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社リプロセル | |
| Company name in english cover page | FilingDateInstant | ReproCELL Incorporated | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 横山 周史 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県横浜市港北区新横浜三丁目８番11号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)045-475-3887（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営管理部マネージャー 鳥澤 雄一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県横浜市港北区新横浜三丁目８番11号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)045-475-3887（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)経営管理部マネージャー 鳥澤 雄一 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E27585 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 49780 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社リプロセル | |
| Filer name in english | FilingDateInstant | ReproCELL Incorporated | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |